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Abstract
Background: We recently completed a randomized clinical trial of two minimally invasive surgical procedures for
stress urinary incontinence, the retropubic tension-free vaginal tape (TVT) versus the trans-obturator tape (TOT)
procedure. At one year postoperatively, we were concerned to find that a significant number of women had tape
that was palpable when a vaginal examination was undertaken. Because the risk factors for adverse outcomes of
tape surgery are not clearly understood, we are unable to say whether palpable tapes will lead to vaginal erosions
or whether they merge into vaginal tissue. We do not know whether patients go on to have further adverse
consequences of surgery, leading to additional cost to patients and healthcare system. Our current study is a 5
year follow-up of the women who took part in our original trial.
Methods/Design: All 199 women who participated in our original trial will be contacted and invited to take part
in the follow-up study. Consenting women will attend a clinic visit where they will have a physical examination to
identify vaginal erosion or other serious adverse outcomes of surgery, undertake a standardized pad test for urinary
incontinence, and complete several health-related quality of life questionnaires (15D, UDI-6, IIQ-7). Analyses will
compare the outcomes for women in the TOT versus TVT groups. The cost-effectiveness of TOT versus TVT over
the 5 years after surgery, will be assessed with the use of disease-specific health service administrative data and an
objective health outcome measure. A cost-utility analysis may also be undertaken, based on economic modeling,
data from the clinical trial and inputs obtained from published literature.
Discussion: This study is needed now, because TOT and TVT are among the most frequently conducted surgical
procedures for stress urinary incontinence in Canada. Because stress urinary incontinence is so common, the
impact of selecting an approach that causes more adverse events, or is less effective, will have a significant impact
on individual quality of life, and societal and health care costs.
Trial registration: ClinicalTrials.gov NCT00234754. Registered October 2005.
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A 2010 Health Canada notice described “Complications
Associated with Transvaginal Implantation of Surgical
Mesh for the Treatment of Stress Urinary Incontinence
and Pelvic Organ Prolapse“ [1]. The warning highlighted
longer term complications associated with the use of
transvaginally-placed mesh for the treatment of stress
urinary incontinence (SUI), including erosion of the
tape through the vaginal epithelium, pain including dys-
pareunia, and infection. The notice also stated that risk
factors associated with these complications are not com-
pletely understood. Health Canada therefore advised
surgeons to seek specialist training in the use of mesh
devices, to discuss possible adverse events with patients
before surgery, and to warn patients that additional sur-
gery may be required to address complications. They
also noted that such surgery may not fully correct any
adverse effects. A similar memo was circulated by the
FDA in 2008, stating that over 1000 adverse events had
been reported [2].
New devices are being introduced frequently for SUI,
because it is a common condition [3-5] which is becom-
ing more prevalent as a result of our aging population
[4-6]. In addition, many patients are less tolerant of
symptoms, embarrassment and inconvenience caused by
SUI [6].
There has been increasing concern about the intro-
duction of new surgical devices into urogynaecology
without evidence of safety and effectiveness[7-9]. Device
manufacturers are not required to provide such infor-
mation to obtain a license in Canada, the USA or Eur-
ope, if a device is made by a manufacturer who makes
similar products or if a similar product is already pro-
duced by another manufacturer [10-12]. Therefore it
becomes the responsibility of clinicians to evaluate any
known relevant evidence [7-9,13]. Unfortunately even if
short-term outcome is known, longer term outcomes
usually remain unknown, and therefore clinicians are
unable to fully inform patients of the consequences of
surgery.
Clinical trials in surgery are difficult to do, particularly
when new devices are widely adopted early [13]. There
is no incentive for device manufacturers to provide
long-term evidence of safety and effectiveness, and it is
difficult for independent researchers to obtain funding,
because there is a perception that licensed devices must
be safe. In addition, it is difficult to recruit patients to
device trials [14,15]. Thus there is a scarcity of longer
term evidence.
We recently completed a randomized clinical trial of
two stress incontinence procedures, finding concerning
clinical outcomes at one year, with a significant number
of women having tape that was palpable when a vaginal
examination was undertaken at one year [16]. Because
the risk factors for adverse outcomes of tape surgery are
not clearly understood [1,2], we are unable to say
whether palpable tapes will lead to vaginal erosions or
whether they merge into vaginal tissue. We do not
know whether patients go on to have further adverse
consequences of surgery, leading to additional cost to
patients and healthcare system.
The problem to be addressed
Stress urinary incontinence (SUI)
Urinary incontinence (UI) is a prevalent condition
that affects approximately 27% of women worldwide
[3,5] with far-reaching physical, psychological, social,
and economic implications. Incontinence has been
found to reduce health-related quality of life to
roughly the same degree as chronic conditions such
as depression and Type I diabetes [17]. Personal con-
sequences include restriction of physical and social
activity, self-imposed social isolation [18,19], and sex-
ual dysfunction [20]. UI is also a major factor contri-
buting to nursing home admission and hospital
readmission among older women with co-morbid
conditions [21,22]. With direct costs estimated at
over 25 billion dollars per year in the United States
(approximately 3,500 dollars for each incontinent per-
son) [23,24] and 1.5 billion dollars per year in Canada
[25], UI is associated with major individual, societal,
and health care costs.
SUI is the most common form of UI in women 60
years of age or younger and is a contributing factor for
the majority of older women with incontinence [26,27].
Women with SUI experience leakage associated with
increases in intra-abdominal pressure, such as with phy-
sical exertion, coughing, laughing, and/or sneezing. Phy-
siological factors include anatomical defects in pelvic
support structures and/or neuromuscular dysfunction
affecting urethral pressure [28]. Women with a family
history of SUI are twice as likely to have SUI compared
to those without a family history [5]. A predisposition
gene for pelvic floor disorders including SUI was
recently described [29]. First line treatment is usually
conservative, for example for example pelvic floor mus-
cle exercises [30]. In cases where conservative therapies
fail, women may opt for surgical treatment [31]. Surgical
treatments for SUI are among the most common of all
female surgeries [32].
Tape surgeries for SUI
Since it was introduced in 1996, the minimally invasive
retropubic tension-free vaginal tape (TVT) [33-41] has
become the surgery of choice for treating stress urinary
incontinence. Concern about complications associated
with TVT [37-41] led in 2001 to the development of
another minimally invasive procedure using the trans-
obturator tape (TOT) procedure [42].
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gary, we conducted a trial of 52 TOT procedures, using
the Obtape device. At 12 months postoperatively, the
vaginal erosion rate was found to be unacceptably high
(15%) [43]. We believed that the high rate of erosions
was associated with the specific polypropylene mesh
( p o r es i z e5 0μm )u s e di nt h eO b t a p ed e v i c e[ 4 4 ] ,b u t
we remained concerned that the trans-obturator
approach itself could be at fault. We decided to under-
take a randomized trial comparing TOT to TVT using
surgical devices from a single manufacturer, that incor-
porated a type of polypropylene mesh which was com-
pletely macroporous (pore size >75 μm), to permit
infiltration by macrophages, fibroblasts and blood ves-
sels [44]. Our trial was designed to compare the effec-
tiveness of the surgical approach of TOT to TVT in
terms of objective cure of stress urinary incontinence
(SUI) at 12 months postoperatively (NCT002237540)
[16]. We also conducted a health economic evaluation
alongside the RCT [45].
In our RCT, women with SUI were randomly allo-
cated to either TOT or TVT procedures, and reviewed
at 12 months after surgery. Primary outcome was objec-
tive evidence of “cure” evaluated by standardized pad
test ("cure” defined as <1 g urine leaked). Other out-
comes included: complications; subjective cure; inconti-
nence-related quality of life; return to usual sexual
activity; and satisfaction with surgery. Primary analysis
compared the proportion of patients in each group who
were cured at 12-month follow-up.
One hundred and ninety-nine women were rando-
mized (94 in the TOT, 105 in the TVT group). 68
women (81%) in the TOT group were cured, versus 67
(77%) in the TVT group (RR 1.05, 95%CI 0.90 to 1.23, p
= 0.58). On vaginal exam, the tape was palpable for 68
women (80%) in the TOT and 24 (27%) in the TVT
group (RR 0.22, 95%CI 0.13 to 0.37, p < 0.001), and
more women in the TOT group experienced groin pain
during vaginal palpation (13 (15%) versus 5 (6%) in the
TVT group, p = 0.04). Quality of life improved signifi-
cantly from baseline in both groups (30 point improve-
ment in IIQ-7 score, both groups).
At 12 months, the majority of women had minimal
leakage, and their quality of life had improved signifi-
cantly, but differences were not observed between
groups. The presence of palpable tape, particularly
among the TOT group, was concerning: longer follow-
up is needed to estimate if this outcome leads to vaginal
erosion or resolves over time. We concluded that until
long-term follow-up is available, TVT should remain the
mid-urethral sling procedure of choice [16].
Our economic evaluation was a cost utility analysis,
using data collected in the trial, as well as administrative
utilization and cost data [45]. The findings from the
cost utility analysis suggest that TOT is a cost-effective
alternative to TVT in the treatment of SUI, perhaps as a
result of underlying difference in utilization of various
health services following randomization [45].
Synthesis
The clinical results from our RCT raise the possibility
that the TOT approach may lead to more women hav-
ing longer term problems if those with tapes found to
be palpable at 12 months go on to develop vaginal ero-
sion. However our economic evaluation suggested that
TOT may be more cost effective than TVT. The appar-
ently contradictory results from our RCT and economic
evaluation must be further investigated, to determine
whether the TOT approach is safe and effective.
Principal research questions
Primary question: safety
What is the incidence of vaginal erosion or other serious
adverse outcomes of surgery among women who had a
surgical procedure for stress urinary incontinence utiliz-
ing a TOT device, versus a TVT device, over the 5 years
following surgery?
Secondary question: effectiveness
What are the objective and subjective outcomes of TOT
compared with TVT at 5 years following surgery for
SUI?
Secondary questions: health economics
What are the disease-specific rates of health service uti-
lization related to repeat surgical intervention, as well as
surgery and other treatment related to adverse events
for women who had a TOT procedure, versus those
who had a TVT procedure, over the 5 years after
surgery?
Using economic modeling and cost utility analysis, is
TOT cost-effective compared with TVT over the 5 years
after surgery?
Other question
Do women with tape found to be palpable in the vagina
at 12 months postoperatively, go on to develop vaginal
erosion by 5 years following surgery?
Literature review
Unfortunately there is very little evidence from clinical
trials related to follow-up of patients for longer than a
year after TOT versus TVT surgery.
Safety
A recent Cochrane review found that minimally invasive
suburethral sling procedures (such as TOT and TVT)
used for the surgical management of SUI produced
more bladder perforations (TVT), but fewer other
operative or short-term postoperative complications
than traditional surgical procedures (such as slings, ret-
ropubic colposuspension and laparoscopic colposuspen-
sion) [46]. The review stated that minimally invasive
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choice for SUI.
Three published systematic reviews with meta analyses
compared complications rates associated with TOT ver-
sus TVT [47-49]. The reviews overlapped, presenting
information on short-term outcome: Sung’ss t u d y
included six RCTs [47], Novara’si n c l u d e d1 4[ 4 8 ] ,a n d
Latthe’s included 11 [49]. The TOT procedure produced
fewer bladder perforations and hematomas, but more
patients had groin pain at two months postoperatively.
The meta analyses did not demonstrate significant dif-
ferences in erosion rates or overactive bladder. Few of
the included trials reported longer term follow-up (over
12 months), and the outcomes evaluated varied widely.
In addition, most of the studies were described as being
of limited methodological and clinical quality, and there-
fore the authors recommended that high-quality studies
with longer term follow-up were needed [47-49]. A
further review of literature published between January
2008 and January 2009 (including six RCTs) came to
similar conclusions [50].
Despite the large number of trials of TOT versus
TVT, the lack of long-term follow-up prevents surgeons
and patients from being able to make treatment deci-
sions on the basis of evidence of safety.
Effectiveness
The recent Cochrane review found that minimally inva-
sive suburethral sling procedures (such as TOT and
TVT) are as effective as traditional surgical procedures
in the short-term [46]. Sung, Novara, Latte and Long
examined the evidence of short-term effectiveness of
TOT versus TVT, concluding that despite the large
volume of research, there is no clear evidence to suggest
that one of the two procedures is preferable to the other
[47,49-51]. The maximum previously reported follow-up
was 36 months [51]. The four reviews concluded that
longer term follow-up is needed before a recommenda-
tion can be made regarding effectiveness.
Health economics
Despite the acknowledged cost of incontinence and con-
cern about the economic burden of disease [23-25], few
studies have examined the economics of surgical proce-
dures for stress urinary incontinence. Papers have exam-
ined the costs of TOT versus Burch colposuspension
[52,53], and TOT versus other surgical procedures [54].
TOT was found to be more cost-effective than other
surgical procedures using RCT data up to 6 months
[52], and using economic modeling up to 5 years [54]
and 10 years [53].
A single study, using retrospective chart data and a
Markov modeling, evaluated the cost of TOT under-
taken as an inpatient procedure versus TVT as day
s u r g e r yp r o c e d u r e ,f i n d i n gt h ed a ys u r g e r ym o r ec o s t
effective than inpatient surgery [55], but not
commenting on the cost effectiveness of TOT versus
TVT.
Our own economic evaluation using the data follow-
ing women to 12 months in our TOT-TVT trial [45],
suggested that TOT is a cost effective alternative to
TVT in the treatment of SUI. However, these results
must be confirmed using longer term follow-up.
Summary
The evidence from published studies provides evidence
of safety and effectiveness in favour of TVT as a surgical
treatment for SUI compared to more traditional
approaches. Unfortunately there is insufficient evidence
to compare the long-term outcome of TOT versus TVT
as a treatment for SUI. Similarly, insufficient economic
evidence is available to evaluate cost effectiveness or
cost utility of TOT versus TVT. Our proposed study
will address these issues.
Methods/Design
Trial design
The research is an extension to a trial previously con-
ducted [16]. The new study further evaluates the safety,
effectiveness and cost utility of the two devices, TOT
and TVT. The study involves follow up of all partici-
pants from the initial trial, and includes physical exami-
nation and quality of life measurement. In addition, a
health economic study is being undertaken. Ethics
approval was provided by the University of Calgary Con-
joint Health Research Ethics Board, Ethics ID 18421.
Trial centres
Patients were initially recruited from three Calgary cen-
tres, with all follow-up carried out at the Calgary Pelvic
Floor Disorders Clinic. All 5 year follow-up visits will
similarly be conducted in the Pelvic Floor Disorders
Clinic.
Inclusion/exclusion criteria
All women included in the initial trial will be eligible for
inclusion in the 5 year follow-up study.
Inclusion criteria
Women were included if they:
￿ had type II stress incontinence, defined as leaking
with increased abdominal pressure [56,57].
￿ were eligible for both types of surgery.
Exclusion criteria
Women were excluded if at the time of the index sur-
gery they:
￿ had vaginal prolapse requiring surgical repair at the
same time as the index surgery
￿ had previously had incontinence surgery
￿ had overactive bladder or incontinence caused only
by bladder overflow
￿ intended to have further children
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neurological disease such as multiple sclerosis, or were
immunocompromised
￿ were unable to understand English.
Trial interventions
Women in the trial received the following interventions
[16]:
Surgical care
All seven surgeons who participated in the trial were
trained to undertake both the TOT and TVT proce-
dures, and had carried out a minimum of 5 of each pro-
cedure as lead surgeon after training. At the time of the
initial study, the TVT procedure was the surgical stan-
dard of care for stress incontinence in Calgary, and
remains so to date.
Women in both groups had their surgery performed
according to the usual practice of the operating surgeon.
Anaesthesia was either general or local, depending on
the clinical state and choice of the patient, and accord-
ing to the usual clinical practice of the anaesthesiologist.
Where possible, the operations were planned as day
procedures.
TOT Group
The TOT procedure was carried out according to the
device manufacturer’s recommendations.
TVT Group
The TVT procedure was carried out according to the
device manufacturer’s recommendations.
Post-operative care for all patients
As usual in Calgary for day case patients, trial partici-
pants in the trial were cared for in their homes, unless a
hospital stay was required for clinical or administrative
reasons.
Practical arrangements for allocating participants to trial
groups
Consenting patients were randomly allocated to receive
either a TOT procedure or a TVT procedure. The ran-
domization list was generated by the study statistician
(using ralloc procedure in Stata (StataCorp LP, Texas,
USA)) using permuted block randomization with block
sizes varying from 2 to 8, and stratified by surgeon. Ran-
domization was carried out a few days before surgery, to
ensure that the appropriate surgical device was available
in the operating room.
Methods for protecting against sources of bias
The initial trial was undertaken as a pragmatic trial [58].
Neither surgical team nor patient knew the next treat-
ment allocation. Outcome measurement was not carried
out blindly, but was conducted by a research nurse who
was independent of clinical care. The vaginal examina-
tions to palpate for tape erosion and pain were carried
out by a clinician (MR) who had recruited 24 of the
study patients. Although noti n f o r m e do ft h ep a t i e n t ’s
group of allocation at the time of vaginal examination, it
became apparent that palpable tapes tended to be asso-
ciated with TOT, and it was therefore not possible to
maintain examiner blinding.
In the 5 year follow-up, similar considerations will
apply. The research nurse who carried out the 12
month contacts and follow-up visits, and is therefore
already known to study patients, will contact and follow
all women at 5 years. The research nurse remains inde-
pendent of clinical care. For the 5 year follow-up, all
clinical examinations will be carried out by a urogynae-
cology clinical fellow who will be blinded to both group
of allocation, and the presence of palpable tape at 12
months.
Frequency and duration of follow up
The current study will follow-up all women who partici-
pated in the trial at 5 years following surgery.
Primary and secondary outcome measures
Primary outcome
Incidence of vaginal erosion or other serious adverse
outcome of surgery (requiring additional treatment)
over the 5 years following surgery.
Secondary outcomes
Objective outcome of SUI surgery at 5 years after index
surgery.
Subjective outcome at 5 years following index SUI
surgery.
Point prevalence of palpable tape, vaginal erosion or
other serious adverse outcomes at 5 years after index
SUI surgery.
Outcome measures be measured at 5 year follow up
All outcomes will be measured at 5 years following
index surgery.
Primary outcome: incidence of vaginal erosion or other
serious adverse outcome
￿ Incidence of vaginal erosion will be determined by
chart review and by standardised digital vaginal exam by
a blinded examiner at the time of follow-up. The
blinded examiner, a urogynaecology fellow, will be
trained to undertake the standardized vaginal exam by
MR. Any women who had additional treatment for vagi-
nal erosion (any surgical treatment, or conservative
treatment with vaginal estrogen), or who is found to
have an erosion on digital exam, will be considered to
have had a vaginal erosion.
￿ Other serious adverse outcomes will be defined as
those occurring during the 5 years following index sur-
gery which are considered to have a suspected “reason-
able causal relationship” [59] with the TOT or TVT
Ross et al. BMC Women?’?s Health 2011, 11:34
http://www.biomedcentral.com/1472-6874/11/34
Page 5 of 12procedure. The adverse outcome will have resulted in
further inpatient or outpatient treatment, an additional
surgical or medical intervention, and/or cause persistent
disability or incapacity. Possible adverse outcomes will
include persistent groin pain and re-operation for SUI.
Women will be asked to recall any problems they
believe they experienced as a result of surgery, and hos-
p i t a lc h a r t sw i l lb er e v i e w e df o ra n yp o s s i b l ea d v e r s e
outcomes or complications. Details of additional treat-
ment will be sought from the treating physician if treat-
ment was provided elsewhere.
￿ An independent adjudication committee will be
established to adjudicate all instances of a primary out-
come (vaginal erosion or other serious adverse out-
come). The adjudication committee will consist of three
urogynaecologists not involved in the trial, from other
institutions than the University of Calgary. They will be
provided with all clinical details of the adverse outcome,
with the cases blinded to group of allocation. The com-
mittee will be asked to judge whether each outcome can
be defined as a serious adverse outcome and whether it
has a “reasonable causal relationship” with the index
surgery. Only if the adjudication committee agrees on
both counts, will the adverse outcome be considered a
primary outcome.
Secondary outcomes
Objective outcome of SUI surgery at 5 years after
index surgery, measured by pad test Objective evi-
dence of SUI at 5 years following surgery will be
obtained using a standardised pad test (as used in our
12 month follow-up [16]), as follows.
￿ Retrograde filling of bladder with 300 ml sterile
water
￿ Pre-weighed collecting device (pad) is put on and
the test period begins
￿ During a 15 minute period the subject performs the
following activities: walk up and down 1 flight of stairs;
standing up from sitting, 10 times; coughing vigorously,
10 times; running on the spot for 1 min; bending to
pick up small object from floor, 5 times; washing hands
in running water for 1 min
￿ At the end of the test the collecting device is
removed and weighed
￿ If test is representative, subject undertakes uroflow
evaluation (check for voiding dysfunction)
Women will be considered “cured” if the pad weight
gain is less than 1 g over the test period. This definition
of cure was used in our earlier follow-up [16], allowing
comparison with that study. This definition has also
been used in other incontinence RCTs [34,60].
Subjective outcome at 5 years following index SUI
surgery Definitions of subjective outcomes will be those
used in our earlier 12 month follow-up [16].
￿ Subjective cure is defined as either ‘no’ experience
of stress incontinence, or if urine loss has been ‘no pro-
blem at all’ or a ‘small problem’:
In the past 7 days, have you lost or leaked urine
when you coughed, laughed, sneezed, lifted, exer-
cised, etc?
[]N o[]Y e s
® If ‘yes’, how much of a problem has this been
for you? (Mark ONE ONLY)
[ ] No problem at all
[ ] A small problem
[ ] A big problem
The seven day recall period captures information on
women who are experiencing regular problematic
incontinence.
￿ Incontinence-related quality of life is measured
using the Urogenital Distr e s sI n v e n t o r y( U D I - 6 ) ,a6
item measure of urogenital distress, and Incontinence
Impact Questionnaire (IIQ-7), a 7 item measure of
incontinence impact [61]. The UDI-6 produces a single
index indicating overall symptom distress and the IIQ-7
produces a single summary index of impact (0 no
impact/distress to 100 maximum impact/distress). Both
measures were developed for use as outcomes in trials
of incontinence treatments: both have been indepen-
dently validated [62-64], and widely used in a variety of
trials [65].
￿ Non-disease specific health related quality of life
(15-D) is measured (as in our earlier study [16]) using
the 15D questionnaire, a validated non-disease specific
health-related quality of life (HRQoL) instrument, based
on the application of multi-attribute utility theory [66].
It consists of 15 dimensions representing attributes of
personal health and activities of daily living. A single
index score, with limiting values of 0 (= dead) and 1 (=
no health problems), will be derived from the results of
each questionnaire by applying Finnish population based
utility weights [66]. Evidence suggests that utility
weights are applicable across geographical locations [67].
Patients completed the 15D questionnaire at baseline, 6
weeks and 12 months, and will be asked to repeat the
questionnaire at 5 years. The index scores of the four
observations will be combined using the area under the
curve method to derive patient-specific QALYs [67-69].
The mean QALY difference between study groups will
be adjusted for the difference between baseline utility
scores [68].
P o i n tp r e v a l e n c eo fp a l p a b l et a p e ,v a g i n a le r o s i o na t
5 years after index SUI surgery Point prevalence of
palpable tape and vaginal erosion will be measured by
standardised digital vaginal exam by a blinded examiner.
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We assume a 20% loss to follow-up from the original
study, and therefore we estimate the sample size will be
approximately 75 in the TOT and 84 in the TVT group.
Possible event rates are noted in systematic reviews,
although these estimates arel i m i t e db yt h em e t h o d o l o -
gical quality and short-term follow-up of the studies
included:
Assuming that our longer follow-up will lead to
increased incidence of adverse outcomes, and because of
our concern about the high rate of palpable tapes at 12
months, we estimate that the primary outcome (inci-
dence of vaginal erosion or other serious adverse out-
come) could be as high as 27% in the TOT group and
12% in the TVT group. If our estimates prove to be cor-
rect, our study would have 70% power to detect such a
difference (2-sided p = 0.05%) and the resulting p-value
would be 0.016 from the comparison of the two propor-
tions using a chi-square test.
If our estimates of effect size prove to be inaccurate,
the study will nonetheless provide important clinical
and economic information on which to base treatment
decisions, because it is the only trial with this length of
systematic outcome evaluation.
Recruitment rate
All women will be contacted initially by mail by the
research nurse who did all the patient contact and fol-
low-up evaluations at 12 months. Following the initial
mail contact, which will include a description of the
study and a consent form, women will be contacted by
telephone to schedule a clinic visit. Women will be con-
tacted for the new study two months before their 5 year
anniversary, so that follow-up appointments can be
scheduled to coincide as closely as possible with the
anniversary of patients’ index surgeries. Initial surgeries
took place over a 21 month period, and therefore the 5
year follow-up visits will take place over a 21 month
period, from October 2010 to June 2012.
We believe that we shall achieve good follow-up rates
for this study. At 12 months follow-up, 182/199 (91%)
study patients participated. We additionally sought con-
sent from women to contact them again at 5 years post-
operatively. We obtained consent from 171/199 patients
(86%), with no responses from 28 patients (16 from the
TOT group, 12 from the TVT group). Among
respondents, no patients refused to be contacted at 5
years. We believe that the non-responding patients may
have moved away and are in the process of re-tracing
them. If we assume that all the women who have not
responded are either lost to the study because they have
moved away, or else will refuse to join when we do find
them, we shall expect to include 86% of patients. If we
assume a further 6% drop-out because they have moved
away, died, or are unable to take part, that would leave
80% to take part in the study.
The experienced research nurse who is undertaking
the study is already known to all study patients, and has
established a good rapport with them. Follow-up at 5
years will be carried out at the Calgary Pelvic Floor Dis-
orders Clinic. We believe that these factors will prove
important in achieving good follow-up, by reducing the
uncertainty involved in joining the follow-up study [15].
We also considered whether there were additional
strategies that would help to ensure good subject parti-
cipation without being coercive [70]. The only appropri-
ate additional strategy we identified is to use a draw for
a gift voucher. This strategy has been previously used in
research to enhance recruitment [71], and financial
incentives are considered appropriate as long as the
amount is not sufficient to put subjects under pressure
to join [72-74]. We believe that that a draw will be a
useful option to encourage subjects to consider joining
our study, while not pressurizing them to do so. The
Conjoint Health Research Ethics Board approved the
use of a ballot for a spa voucher for $100. Four draws
will be carried out during the course of the study, one
after each group of 50 women.
Statistical analyses
Analysis will be by intention to treat, whereby women
will remain in the group to which they were allocated
by randomization, no matter what surgery they received
either during the initial surgery or later during the 5
years postoperatively. In our trial, only one patient did
not receive the treatment as allocated, a patient whose
TOT procedure was converted to a TVT at the same
surgery after urethral muscles were torn [16]. In all ana-
lyses, this patient has remained in the TOT group to
which she was allocated.
The primary analysis will compare the proportion of
patients who have a vaginal erosion or other serious
adverse outcome of surgery requiring surgical or other
treatment at some point during the 5 year follow-up fol-
lowing index surgery, using a chi-square test. Log bino-
mial regression will be used to adjust the results for any
observed imbalances on baseline characteristics. Imputa-
tion methods will not be used for missing data from
absence of consent or dropout. Results will be reported
according to the CONSORT Statement extension for
Table 1 Adverse outcome rates reported in systematic
reviews
Adverse Outcome Reference Follow-up TOT TVT
Vaginal erosion Long [50] ≤ 12 months 4% 1%
Groin pain Long [50] ≤ 12 months 6% 2%
Re-operation rate Novara [48] up to 16 months 2% 3%
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analyses:
￿ Objective urinary incontinence: the proportion of
patients “cured” (leaking < 1 g urine on pad test) at 5
years following index surgery will be compared using a
chi-square test.
￿ Subjective urinary incontinence: the proportion of
patients reporting no/little problematic stress inconti-
nence in the past 7 days, at 5 years following surgery
will be compared using a chi-square test.
￿ Incontinence-related quality of life: the mean
scores of UDI-6 and IIQ-7 will be compared between
the two groups using analysis of covariance adjusting for
baseline score.
￿ Prevalence of palpable tape or erosion: the propor-
tion of patients with palpable tape or erosion will be
compared between groups using a chi-square test. A
McNemar chi-square test will be performed to assess
whether there is a relationship between having palpable
tape or erosion at 12 months, and having of palpable
tape or erosion at 5 years following surgery.
Frequency of analyses
A single statistical analysis is planned, after all of the
patients have been followed up, and all data are com-
plete. Similarly a single cost-utility analysis is planned
after all trial, resource utilization and cost data are com-
plete. No subgroup analyses are planned.
Economic evaluation
Replicating our empirical cost-utility analysis [45] in
a study which spans 5 years presents two specific
challenges. Since the health effect (measured by
QALYs) would be based on only 4 observations
(baseline, 12 weeks, 1 year and 5 years following sur-
gery) any differences in health outcome between the
study arms that occur between years 1 and 5, but are
resolved by the end of year 5, will not be reflected in
the aggregate QALY calculation. A second challenge
relates to cost. Over the course of the 5 year period
it is likely that disease-specific costs will represent
only a small proportion of total health care costs,
which relate to all causes. In this event, a significant
difference in disease-specific costs between the study
arms may not be reflected at the level of aggregate
total costs.
To address these potential challenges we have outlined
two analyses: an empirical analysis which focuses on
health service utilization that is disease-specific, and a
cost utility analysis that is based on decision analytic
modeling, which will allow us to measure health effect
in more frequent shorter intervals (e.g. annually) during
the follow-up period and incorporate only disease-speci-
fic costs.
Health service utilization
Data will be sought from a variety of sources to ensure
that we capture all condition-specific health services uti-
lization related to repeat surgical intervention, as well as
surgery and other treatment related to adverse events.
Patients will be asked if they have needed any treat-
ment for SUI or possible adverse effects of surgery in
the 5 years following surgery. This approach may be
limited because of recall bias, and therefore it will be
only one of a number of approaches.
Alberta Health Services, the province-wide provider
of health services, provided health care utilization data
for our previous study, identifying inpatient and ambula-
tory hospital services. For the 5-year follow-up, we shall
seek information in a similar way, using codes for diag-
noses and procedures. For diagnoses we shall use ICD-
10-CA, an enhanced version of ICD-10 developed by
Canadian Institute for Health Information (CIHI) for
morbidity classification in Canada [75]. For procedures
we shall use the Canadian Classification of Health Inter-
ventions (CCI), the Canadian standard for classifying
health care procedures [75]. Together these coding clas-
sifications will enable us to limit our evaluation to
health service use that is related to possible consequence
of SUI surgery.
Alberta Heath and Wellness (AHW), the provincial
health department, will be asked to provide data relating
to the utilization of physician services. The Physician
Payments Data File contains diagnostic data (ICD9-CM)
which will allow us to identify condition-specific physi-
cian services utilization.
Health services utilization will be described for each
group. Comparisons between groups will include num-
ber of: visits to treat vaginal erosions; visits for treat-
ments related to adverse events; and repeat surgeries for
incontinence. Analyses comparing health services utiliza-
tion between groups will use non-parametric methods.
Cost-utility analysis based on decision analytic modeling
W ep r o p o s et oc o n d u c tac o s tu t i l i t ya n a l y s i sf r o mt h e
public payer perspective with the use of a Markov
model. We will simulate the movement of a theoretical
cohort of SUI patients through a model structure com-
prised of health states that are defined by key health
outcome or health service events in the surgical treat-
ment of SUI.
A proportion of the cohort will move to each of the
health states once per cycle (i.e. a discrete time period,
such as a month or year), in accordance with pre-speci-
fied transition probabilities. As an illustration, the struc-
ture of a five-state model used in a published evaluation
of Burch colposuspension compared with TVT is shown
in the Figure 1 [53, figure one].
Quality of life utility weights (with a value between 0 and
1, derived from 15D [66]) and costs are assigned to each
Ross et al. BMC Women?’?s Health 2011, 11:34
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each cycle of the model the expected cost per patient for
each cycle is a weighted average of the cost of each of the
health states. Summing over the entire time horizon of the
model provides the overall expected cost per patient. A
similar calculation is performed with utility weights to
derive the expected health effect, defined as the average
QALY per patient over the study horizon. Expected cost
and effect are calculated for each study arm, permitting
the calculation of incremental cost and effect. The evalua-
tion will be based on the economic evaluation guidelines
set out by the Canadian Agency for Drugs and Technolo-
gies in Health (CADTH) [76].
T h em o d e ls h o w ni nt h eF i g u r e1w i l lb et h es t a r t i n g
point of our model development. Development of the
appropriate model structure will be an integral element
of this project.
Since only four QALY data observations spread over
five years will be available for analysis (our first trial
combined with this proposed trial) and our sample size
may be too small for some sub-group analyses, we will
supplement trial data with data from published sources
to estimate transition probabilities and utility weights.
For key probabilities, such as the probability of mesh
erosion, we will conduct a new meta-analysis as part of
this project incorporating all trial data to date.
Disease-specific health state costs will be estimated
from administrative data. Utilization data, relating to
inpatient and ambulatory hospital services, will be
obtained as above. Unit costs related to inpatient and
ambulatory care will be obtained from standard cost
estimates provided by the CIHI and AHW, respectively.
Data relating to the cost of physician services will be
obtained from AHW. Costs will be defined with respect
      
Initial
surgery
 
    
           
 
 
 
 
Cure   Persistent 
SUI with 2
nd
surgery
  Persistent
SUI 
  Mesh 
exposure
 
Notes
Arrows indicate direction of movement between health states.  Arrows pointing 
to the same state indicate that a portion of patients remain in that state for 
each cycle of the model.  Transition probabilities are associated with each 
arrow in the diagram. 
Figure 1 Illustrative Markov model structure [53].
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Page 9 of 12to an appropriate reference year. Both costs and QALYs
will be discounted at the standard rate of 3% per year.
The uncertainty associated with the estimation of
input parameters (transition probabilities, utility weights
and costs) will evaluated by a probabilistic sensitivity
analysis. This simulation analysis will be used to derive
a scatter plot of incremental cost and effect, and a cost-
effectiveness acceptability curve. These outputs will be
essential in assessing the potential cost-effectiveness of
the TOT procedure versus TVT. Additional one-way
sensitivity analyses of key parameters and alternative
model structures will be undertaken as necessary.
Discussion
The need for a trial
This trial is needed now, because TOT and TVT are
among the most frequently conducted surgical proce-
dures for SUI in Canada. Because SUI is so common,
the impact of selecting an approach that causes more
adverse events, or is less effective, will have a significant
impact on individual quality of life, and societal and
health care costs.
Manufacturers are not required to produce longer
term follow-up data to obtain licenses for new SUI
devices [7], and therefore this evidence is not available
to health authorities, surgeons and patients when they
decide on a treatment for SUI. Nor have researchers yet
provided longer term evidence to support decision-
making.
The results of this follow-up study will inform both
clinical choice and set a benchmark against which to
judge other surgical trials.
Use of the results of this trial
The results will produce information about the number
of patients who go on to develop vaginal erosions and
other serious outcomes. We believe our systematic fol-
low-up of patients at 12 months following random allo-
cation to TOT or TVT surgery, with the observation of
palpable tapes in a significant number of patients, is the
first such finding, and therefore increasing the duration
of follow-up to five years will provide useful information
about the longer term safety and effectiveness of the
two procedures. These results relating to TOT and TVT
procedures will be used by clinicians and patients in
informing decisions about surgical treatment of SUI.
The information produced from our cost-utility study
can be used by health technology committees (local,
regional, provincial or federal) in advising hospitals and
clinicians about the use of these procedures, taking into
account the cost of the devices and the sequelae of the
procedures over a five-year period.
In addition, our study may be able to produce infor-
mation about any possible link between palpable tape at
12 months after surgery and development of vaginal
erosion and other adverse outcomes. Thus our study
m a yb ea b l et op r o v i d eab e t t e ru n d e r s t a n d i n ga b o u t
the development of erosion of surgical tape into the
vagina.
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